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Quality of life assessment in interstitial
lung diseases:a comparison of the disease-
specific K-BILD with the generic EQ-5D-5L
Boglárka Lilla Szentes1* , Michael Kreuter2, Thomas Bahmer3, Surinder S. Birring4,5, Martin Claussen3,
Julia Waelscher2, Reiner Leidl1,6 and Larissa Schwarzkopf1
Abstract
Background: Patients with interstitial lung diseases (ILD) have impaired health-related quality of life (HRQL). Little is
known about the applicability of the disease-specific King’s Brief Interstitial Lung Disease questionnaire (K-BILD)
and the generic EQ-5D-5L in a German setting.
Methods: We assessed disease-specific (K-BILD) and generic HRQL (EQ-5D experience based value set (EBVS) and
Visual Analog Scale (VAS)) in 229 patients with different ILD subtypes in a longitudinal observational study (HILDA).
Additionally, we assessed the correlation of the HRQL measures with lung function and comorbidities. In a linear
regression model, we investigated predictors (including age, sex, ILD subtype, FVC percentage of predicted value
(FVC%pred), DLCO percentage of predicted value, and comorbidities).
Results: Among the 229 patients mean age was 63.2 (Standard deviation (SD): 12.9), 67.3% male, 24.0% had
idiopathic pulmonary fibrosis, and 22.3% sarcoidosis. Means scores were as follows for EQ-5D EBVS 0.66(SD 0.17),
VAS 61.4 (SD 19.1) and K-BILD Total 53.6 (SD 13.8). K-BILD had good construct validity (high correlation with EQ-5D
EBVS (0.71)) and good internal consistency (Cronbach’s alpha 0.89). Moreover, all HRQL measures were highly
accepted by patients including low missing items and there were no ceiling or floor effects. A higher FVC % pred
was associated with higher HRQL in all measures meanwhile comorbidities had a negative influence on HRQL.
Conclusions: K-BILD and EQ-5D had similar HRQL trends and were associated similarly to the same disease-related
factors in Germany. Our data supports the use of K-BILD in clinical practice in Germany, since it captures disease
specific effects of ILD. Additionally, the use of the EQ-5D-5L could provide comparison to different disease areas
and give an overview about the position of ILD patients in comparison to general population.
Keywords: ILD, Health-related quality of life, K-BILD, EQ-5D-5L, Comorbidities
Background
Interstitial lung diseases (ILDs) comprise more than 200
rare diseases, which are characterized by varying degrees
of inflammation and fibrosis of the lung, and are
associated with serious quality of life impairments in af-
fected people [1–5]. There were attempts to quantify the
health-related quality of life (HRQL), however most
previous analyses focused on the most prevalent
forms of ILDs (i.e. Idiopathic Pulmonary Fibrosis
(IPF), Sarcoidosis) e.g. Kreuter et al. provide data
about the German IPF population [6] or did not
apply ILD-specific assessment tools [6–13]. Instead,
among others, questionnaires originally designed for
patients with Chronic Obstructive Pulmonary Disease
(COPD) were tested in ILD-populations: e.g. the
COPD Assessment Test [7] and the St George’s Re-
spiratory Questionnaire (SGRQ) [5, 8]. The suitability
of these questionnaires to reflect ILD-specific aspects
of HRQL remains up to discussion. Moreover, given
the heterogeneous clinical course of ILDs, a transferability
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of HRQL findings among patients with IPF or sarcoidosis
to other ILD subtypes is a highly sensitive issue.
Keeping these drawbacks in mind, all studies cited sug-
gest impaired HRQL in ILD patients but comprehensive
analyses of HRQL in ILDs accounting for many different
subtypes and focusing on disease-specific questionnaires
are sparse.
Recently the King’s Brief Interstitial Lung Disease
Questionnaire (K-BILD) [9] has been proposed as the
first and so far only ILD-specific HRQL assessment tool.
The K-BILD is a validated [10] and clinically oriented
HRQL tool [11]. Evidence shows that K-BILD is a suit-
able HRQL measure in different countries; e.g. in UK [9]
and in Italy, France, Sweden and the Netherlands as
shown by Wapenaar et al. [10] However, until now there
is no study using K-BILD in a German setting beyond
Kreuter et al. that have translated and validated the
questionnaire [12] in 2016.
To compare the disease burden of ILD patients with
the general population or with patients suffering from
different diseases, the use of a generic HRQL instrument
is recommended, since generic questionnaires measure
overall HRQL and not just disease-specific primarily
symptom-driven aspects, which would not apply for
every group [14]. The EuroQol group developed the
generic EuroQol five dimensional 5-Level (EQ-5D-5L)
questionnaire, which is the improved version of the
well-known and well-established 3-level version;
EQ-5D-3L [13]. Thus, we assume that the 5L version
would provide a good insight in the generic HRQL in the
ILD patients and allows the comparison with
disease-specific measures. The use of the EQ-5D-5L in
lung disease patients is spare so far [10, 15, 16], and there
is no validation in the ILD disease-area yet.
Therefore, in the first step we aimed to investigate the
suitability of the K-BILD in Germany to measure
ILD-specific HRQL. In the second step we aimed to meas-
ure psychometric values of the EQ-5D-5L compared to
the K-BILD and thereby contribute to a validation of the
generic HRQL measure in the disease group ILD. Further-
more, we want to give first insights into HRQL of ILD pa-
tients and its predictors in a German tertiary care setting.
Methods
Study population and data collection
Data is derived from the ongoing HILDA (Health Care
in ILD Ambulance Visitors) study. This observational
study addresses outpatients diagnosed with any ILD sub-
type who presented to the outpatient practices of two
large German tertiary care centers for ILD in Germany
(Thoraxklinik Heidelberg, LungenClinic Großhansdorf ).
Heidelberg is a city in south-west Germany whereas
Grosshansdorf is in the Northern part. Participants were
recruited sequentially over a period of six months
starting in November 2016. The local Ethics Committees
of Heidelberg and Luebeck approved the study (refer-
ence number S-200/2013, and AZ: 16-192, respectively).
Participants provided written informed consent.
Individuals who were 18 years of age and older, with
ILD confirmed by the ILD boards of the respective cen-
ters, with an expected survival time of more than
12 months and with sufficient knowledge of the German
language were eligible for the HILDA-study. Participants
were grouped to one of the following ILD subtypes: ‘IPF’,
sarcoidosis, Hypersensitivity Pneumonitis (HP), other
Idiopathic Interstitial Pneumonias (than IPF) (‘other IIP’),
and other ILDs based on the differential diagnosis of the
treating clinician. ‘Other IIP’ accounts for idiopathic inter-
stitial pneumonia, non-specific interstitial pneumonia,
desquamative interstitial pneumonia, cryptogenic organiz-
ing pneumonia, lymphocytic interstitial pneumonia, re-
spiratory bronchiolitis-associated interstitial lung disese,
pleuropulmonary fibroelastosis, and acute interstitial
pneumonia, while the ‘other’ group includes every other
subtype not listed above.
HRQL assessment
The patients’ self-reported HRQL was assessed at time of
inclusion (at baseline) into the HILDA registry as part of
their regular ambulance visits using EQ-5D-5L (generic
HRQL) [17] and K-BILD [9] (disease-specific HRQL).
a) EQ-5D-5L
The generic EQ-5D-5L consists of two parts, the de-
scriptive system and a Visual Analogue Scale. The descrip-
tive system addresses five different dimensions (‘mobility’,
‘self-care’, ‘usual activities’, ‘pain/discomfort’, and ‘anxiety/
depression’), each with a five point Likert-Scale. The
answering pattern can be transferred to a utility between 0
and 1 (the higher the better) by distinct (nation-specific)
scoring algorithms [18–21]. We chose the Germany-specific
experience-based value set (EQ-5D EBVS) from Leidl et al.
[18] for calculation of values. The Visual Analog Scale
(VAS) allows valuing current health on a thermometer
scale between 0 and 100, with higher values indicating
better health.
b) K-BILD
K-BILD measures health impairments induced by ILD.
The questionnaire covers 15 questions spread out in three
domains (‘breathlessness and activity’, ‘chest symptoms’
and ‘psychological impact’) via a seven point Likert Scale.
The total (cross-domain) score and domain-specific
subscores range from zero to 100 with higher values indi-
cating better health. Scores can be calculated through a
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predefined, not a patient-reported scoring algorithm,
which is provided by the authors upon request [9].
Assessment of covariables
To reflect potential impact factors on HRQL we
accounted for comorbidity burden, clinical aspects and
the patients’ sociodemographic background.
Comorbid conditions were derived from patients’ his-
tory and medical records. We considered the following
comorbid conditions based on previous evidence on their
ILD-relevance: pulmonary hypertension, arterial hyperten-
sion, coronary heart disease, congestive heart failure, other
cardiovascular disease, diabetes mellitus, emphysema/
COPD, lung cancer, depression, gastroesophageal reflux
disease, renal failure, obstructive sleep apnea, thrombo-
embolism, and malignant tumors other than lung cancer
[22–24]. In addition, physicians were allowed to list up to
three relevant comorbid conditions not included in the
pre-selection. Comorbidity burden was operationalized as
sum of all documented conditions, therefore ranging be-
tween zero and 17.
As clinical routine, we measured forced vital capacity
percent predicted (FVC % pred), and diffusing capacity
of the lungs for carbon monoxide percent predicted
(DLCO % pred) as functional parameters.
We assessed further basic characteristics by
questionnaire-based self-reports of the patients.
Statistical analysis
For our analyses, only patients with complete informa-
tion on HRQL and on all covariables relevant for regres-
sion analyses were included (complete case analysis).
The data from the HRQL questionnaire were considered
complete if the total score could be calculated. To avoid
selection bias, we compared patient characteristics of
those with incomplete and complete questionnaires be-
fore finally excluding any patients from further analyses.
Subsequently, we assessed floor and ceiling effects;
defined as > 15% of the participants achieving the best/
worst HRQL score [25]. Besides, correlations between
the HRQL measures, lung function parameters and the
comorbidity sum score were quantified by Spearman’s
rank coefficient to examine associations. We considered
correlations < 0.3 as weak, those ≥ 0.3 and < 0.7 as
moderate and those ≥ 0.7 as strong [26]. Furthermore,
internal consistency was assessed for the K-BILD do-
mains and total score with Cronbach’s alpha.
Influencing factors on HRQL were investigated via
separate linear regression analyses using EQ-5D EBVS,
VAS, K-BILD and the K-BILD domains as the respective
outcome variables and sex, age (in years), education
(basic ≤ 9 years, secondary 10-11 years, higher ≥ 12 years
of schooling), employment status (full-time, part-time,
unemployed), clinic location (to control also for climate
differences), smoking status (current, former, never
smoker), lung function parameters, disease subtype and
comorbidity sum score as the independent variables.
Reference categories were male, higher education, re-
tired, study center Heidelberg, smoker and ‘other ILD’
respectively. Since the reference category for ILD sub-
type is more arbitrary than for the other covariables, we
conducted least squares mean comparisons to detect
further differences among ILD subtypes.
Given the extended recruitment period (November –
April) we also investigated the potential impact of sea-
sonal fluctuation of respiratory symptoms by including
time of enrolment (winter yes/no) into our regression
models. Since this more complex approach did not have
a substantial additional explanatory effect, we con-
sciously disregarded seasonal aspects within the analyses
to support a straightforward interpretation.
Within a secondary analysis, we included all 14
pre-selected comorbidities to examine the influence of
the distinct conditions on HRQL. Furthermore, in a sen-
sitivity analysis we imputed the missing values except for
our outcome variables (EQ-5D EBVS, VAS and K-BILD,
n = 9). For missing categorical values we used the me-
dian of the observation (education n = 7, smoking status
n = 2), and for missing continuous values the mean of
the observation (DLCO % pred n = 16, FVC % pred
n = 4). For the variable employment we imputed
‘full-time’ under 65 years of age and ‘retired’ above;
according to the German retirement policies (n = 2)
[27]. Additionally, we conducted the secondary analysis
with imputing the lowest DLCO % pred values, in case pa-
tients with missing DLCO values were not able to take the
test and thus assuming low DLCO values.
Statistical analyses were performed with SAS soft-
ware (SAS Institute Inc., Cary, NC, USA, version 9.4),
and p-values of 0.05 or less were considered statisti-
cally significant.
Results
Patient characteristics
Out of the 268 patients we included 229 into final ana-
lyses after excluding 39 (14.6%) with incomplete data.
The excluded patients were similar to the finally in-
cluded study population except for their FVC % pred
(included: 70.4 vs excluded: 53.1 p < 0.0001) and HRQL
(EQ-5D EBVS: 0.66 vs 0.59 p = 0.032; VAS: 61.4 vs. 49.1
p = 0.0005; K-BILD 53.6 vs 48.2 p = 0.0166).
The majority of the included patients was male
(67.3%) with mean age of 63.2 (standard deviation: 12.9)
and around half of the patients were retired. IPF was
present in 24.0% of the patients, 22.3% presented with
sarcoidosis, 11.4% HP, 9.2% ‘other IIP’, and 33.2% other
ILDs (Table 1). Descriptive results stratified by center
are shown in the online supplement; patients in
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Heidelberg were older, have more frequently basic
education, were retired more often, showed higher
comorbidity score and lower DLCO % pred values
but showed no difference in the outcome variables
(Additional file 1). The most frequent comorbidity
was arterial hypertension (41.3%), followed by coron-
ary heart disease (19.5%) and diabetes mellitus
(15.9%). All other comorbidities were present in less
than 10% of the study population.
ILD-specific and generic HRQL
K-BILD showed the least missing values, followed by
VAS and EQ-5D EBVS with two (0.7%), five (1.87%) and
six (2.24%) missing values respectively.
There was no indication for ceiling or floor effects
in any outcome parameter. Regarding generic HRQL,
29 (12.7%) patients had the maximum possible score
for EQ-5D EBVS, three the maximum VAS score, but
no one zero. There was only one patient each within
the best and worst categories for the K-BILD. K-BILD
domains showed also no ceiling or floor effects
(‘breathlessness and activity’ worst 5.2%, best 4.4%,
‘chest symptoms’ 0.4% vs 14.4%, ‘psychological impact’
0.4% vs 0.4%).
Altogether, ILD-specific HRQL had lower values
relative to their scale than generic HRQL (EQ-5D
EBVS: 0.66 and VAS: 61.4 vs K-BILD: 53.6) (Fig. 1)
with the highest impairments occurring in the
‘breathlessness and activity’ domain (unadjusted mean
Table 1 Baseline characteristics of the participants
Characteristic Total sample Excluded p-value
N = 268 Mean/% Mean/% Missing
229(85.5) 39 (14.5)
Sex n(%) Male 154 (67.3) 22 (56.4) 0 0.1876
Age Mean (SD) 63.2 (12.9) 62.0 (13.6) 0 0.677
Education Basic 99 (47.1) 15 (50) 9 0.6694
n(%) Secondary 59 (28.1) 8 (26.7)
Higher 52 (24.8) 7 (23.3)
Employment Full-time 57 (24.9) 11 (29.7) 2 0.1379
n(%) Part-time 24 (10.5) 1 (2.7)
Unemployed 30 (13.1) 9 (24.3)
Retired 118 (51.5) 16 (43.2)
Smoking status Current smoker 9 (3.9) 3 (8.1) 2 0.3797
n(%) Former smoker 139 (60.7) 19 (51.4)
Never smoker 81 (35.4) 15 (40.5)
ILD subtypes IPF 55 (24.0) 6 (15.4) 0 0.1145
n(%) Sarcoidosis 51 (22.3) 7 (18.0)
Hypersensitivity pneumonitis 26 (11.4) 1 (2.6)
Other IIPsa 21 (9.2) 5 (12.8)
Others 76 (33.2) 20 (51.3)
DLCO% predicted Mean (SD) 44.2 (17.2) 44.2 (17.2) 17 0.3187
FVC % predicted Mean (SD) 77.4 (18.9) 53.1 (17.5) 4 <.0001
Mean number of comorbidities Mean (SD) 2.7 (1.8) 2.8 (2.0) 0 0.8936
EQ-5D-5L
Mean (SD)
EBVS 0.66 (0.17) 0.6 (0.2) 6 0.0320
VAS 61.4 (19.1) 49.1 (17.9) 5 0.0005
K-BILD Total score 53.6 (11.7) 48.2 (10.7) 2 0.0166
Mean(SD) Breathlessness and activity 41.1 (20.6) 31.6 (23.3) 0 0.0052
Chest symptoms 64.4 (22.2) 57.4 (22.4) 1 0.0920
Psychological impact 52.2 (13.8) 47.1 (12.1) 2 0.1014
Percentages in the excluded group show the percent of valid answers. Abbreviations: SD Standard deviation, EQ-5D EBVS-EQ-5D experience based value set,
VAS-Visual Analog Scale, IPF-idiopathic pulmonary fibrosis, IIP-idiopathic interstitial pneumonia, EBVS-experience based value. ainlcuding non-specific interstitial
pneumonia, desquamative interstitial pneumonia, cryptogenetic organizing pneumonia, lymphocytic interstitial pneumonia, respiratory bronchiolitis-associated
interstitial lung disease, pleuropulmonary fibroelastosis, and acute interstitial pneumonia
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scores: 41.1 vs. 52.2 ‘psychological impact’ and 64.4
‘chest symptoms’).
Correlation of HRQL assessment tools and internal
consistency
K-BILD total score correlated strongly with the
EQ-5D EBVS (0.71), but only moderately with the
VAS (0.55). All instruments had weak or moderate
correlations with lung function parameters and co-
morbidity burden (Table 2). The K-BILD domains
showed stronger correlations to the EQ-5D EBVS
than to the VAS. Looking at correlations between
the K-BILD and the EQ-5D dimensions, the stron-
gest correlation was found for the ‘breathlessness
and activity’ (K-BILD) with ‘usual activities’ (EQ-5D)
(− 0.69, p < 0.00001) and ‘mobility’ (EQ-5D) (− 0.65,
p < 0.0001). However, further correlations were mod-
erate at best (Table 3).
The K-BILD total score showed the highest internal
consistency with Cronbach’s alpha of 0.89, followed
by the ‘breathlessness and activity’ domain, ‘chest
symptoms’ and psychological impact with values 0.87,
0.74 and 0.73 respectively.
Impact factors on ILD-specific and generic HRQL
In the primary analysis, the strongest influencing factor
for all of the HRQL measures and their domains was
FVC % pred (Table 4). Older age, higher education and
Fig. 1 Unadjusted health-related quality of life results. Abbreviations: EQ-5D EBVS-EQ-5D experience based value set, VAS-Visual Analog Scale
Table 2 The correlation between health status and lung function
EQ-5D
EBVS
VAS K-BILD
Total
K-BILD
Breath
K-BILD
Chest
K-BILD
Psych
FVC %
predicted
DLCO %
predicted
Comorbidity
sum score
EQ-5D EBVS 1
VAS 0.58
(<.0001)
1
K-BILD Total 0.71
(<.0001)
0.55
(<.0001)
1
K-BILD Breath 0.71
(<.0001)
0.58
(<.0001)
0.86
(<.0001)
1
K-BILD Chest 0.60
(<.0001)
0.47
(<.0001)
0.78
(<.0001)
0.61
(<.0001)
1
K-BILD Psych 0.60
(<.0001)
0.49
(<.0001)
0.93
(<.0001)
0.67
(<.0001)
0.69
(<.0001)
1
FVC % predicted 0.30
(<.0001)
0.21
(0.0013)
0.29
(<.0001)
0.36
(<.0001)
0.22
(0.0006)
0.24
(0.0002)
1
DLCO % predicted 0.17
(0.0106)
0.14
(0.0409)
0.27
(<.0001)
0.35
(<.0001)
0.12
(0.0821)
0.22
(0.001)
0.47
(<.0001)
1
Comorbidity sum score −0.26
(<.0001)
− 0.25
(0.0002)
− 0.21
(0.0012)
− 0.28
(<.0001)
−0.16
(0.0173)
− 0.16
(0.0174)
− 0.09
(0.1569)
− 0.26
(<.0001)
1
Abbreviations; K-BILD Breath- K-BILD Breathlessness and activity, K-BILD Chest- K-BILD Chest symptoms, K-BILD Psych- K-BILD Psychological Impact, FVC %
pred –Forced vital capacity % predicted, DLCO % predicted- Carbon monoxide diffusing capacity % predicted. In brackets we reported p-values. We considered
correlations < 0.3 as weak, ≥0.3 and < 0.7 as moderate and ≥ 0.7 as strong
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working full time were associated with higher EQ-5D
EBVS but did not significantly influence K-BILD or VAS.
Patients classified as other ILDs had worse HRQL
compared to IPF patients (measured with EQ-5D
EBVS, VAS and ‘breathlessness and activity’ domain)
or compared to ‘other IIP’ patients (measured with
EQ-5D EBVS and with ‘psychological impact’
domain) (Table 4). Least square mean comparisons
between the remaining groups showed in two cases
a difference in the primary analysis. Regarding
EQ-5D EBVS sarcoidosis patients had lower values
than patients did in the ‘other IIP’ group (− 0.098 p =
0.0278). Moreover, they were significantly more im-
paired in the ‘breathlessness and activity’ domain of
Table 3 Relationship between the different HRQL domains
EQ-5D Mobility EQ-5D Self-care EQ-5D Usual activities EQ-5D Pain/ discomfort EQ-5D Anxiety/ depression
EQ-5D Mobility 1
EQ-5D Self-care 0.51
(<.0001)
1
EQ-5D Usual activities 0.65
(<.0001)
0.54
(<.0001)
1
EQ-5D Pain/ discomfort 0.40
(<.0001)
0.29
(<.0001)
0.49
(<.0001)
1
EQ-5D Anxiety/ depression 0.39
(<.0001)
0.26
(<.0001)
0.44
(<.0001)
0.24
(0003)
1
K-BILD
Breath
−0.65
(<.0001)
− 0.48
(<.0001)
− 0.69
(<.0001)
− 0.45
(<.0001)
− 0.38
(<.0001)
K-BILD
Chest
− 0.49
(<.0001)
− 0.31
(<.0001)
−0.52
(<.0001)
− 0.45
(<.0001)
−0.35
(<.0001)
K-BILD Psych. −0.47
(<.0001)
−0.33
(<.0001)
− 0.53
(<.0001)
−0.39
(<.0001)
− 0.51
(<.0001)
Abbreviations; K-BILD Breath- K-BILD Breathlessness and activity, K-BILD Chest- K-BILD Chest symptoms, K-BILD Psych- K-BILD Psychological Impact. In brackets, we
reported p-values. We considered correlations < 0.3 as weak, ≥0.3 and < 0.7 as moderate and ≥ 0.7 as strong
Table 4 Results of regression analyses for the primary analysis (with comorbidity score)
K-BILD
EQ-5D EBVS VAS Total Breathlessness and activity Chest symptoms Psychological impact
Parameter Estimate Estimate Estimate Estimate Estimate Estimate
Sex (Ref = Male) Female −0.016 2.63 −0.99 −1.39 − 0.90 − 1.49
Age 0.003** −0.02 0.12 0.06 0.22 0.13
Education Basic −0.05* −5.44 −1.85 −4.47 − 1.66 − 0.84
(Ref = higher) Secondary 0.03 −0.65 0.24 0.16 2.86 0.14
Employment Full-time 0.11** 6.05 3.78 5.85 7.19 2.31
(Ref = retired) Part-time 0.07 7.9 3.39 7.26 2.13 3.27
Not employed −0.02 −3.38 −0.23 −1.03 −3.49 −0.19
Clinic (Ref = GH) Heidelberg 0.03 1.86 2.28 3.61 4.25 3.05
Smoking status
(Ref = smoker)
Never smoker 0.03 0.75 6.00 3.01 6.45 9.53*
Former Smoker −0.02 0.45 −2.69 −4.52 −4.71 −2.59
FVC % pred 0.002*** 0.19* 0.15** 0.28*** 0.27** 0.16**
DLCO % pred −0.0004 −0.06 0.07 0.20* −0.004 0.06
Disease Subtype
(Ref = other)
IPF 0.07* 8.39* 3.51 7.85* 3.62 2.71
Sarcoidosis −0.001 −0.49 − 0.90 −4.34 − 5.71 0.67
HP 0.02 0.73 3.33 3.29 4.89 4.43
Other IIPs1 0.09* 8.78 4.70 5.48 1.16 7.29*
Comorbidity sum score −0.03*** −2.72** −1.51** −3.06*** − 2.68** − 1.44*
Values depicted are the beta estimates of regression coefficients. Abbreviations: IPF-idiopathic pulmonary fibrosis, HP-Hypersensitivity pnemonitis, GH-Großhansdorf.
1including: non-specific interstitial pneumonia, desquamative interstitial pneumonia, cryptogenetic organizing pneumonia, lymphocytic interstitial pneumonia,respiratory
bronchiolitis-associated interstitial lung disease, pleuropulmonary fibroelastosis, and acute interstitial pneumonia. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
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K-BILD compared to IPF patients (− 12.19 p = 0.0089)
(Additional file 2).
The secondary analysis revealed two comorbidities
with a significant influence; arterial hypertension was as-
sociated with a lower EQ-5D EBVS (− 0.05 p = 0.0441)
and with a lower score in the ‘breathlessness and activity’
domain (− 6.85 p = 0.0173) (Table 5). Additionally,
depression had a strong negative association with the
‘chest symptoms’ domain (− 17.04 P = 0.0029).
Within the sensitivity analyses (n = 257) results chan-
ged only marginally in terms of effect sizes as well as in
terms of significant levels. Altogether, the results of the
main analyses were mirrored almost perfectly without
any noteworthy exceptions.
Discussion
Here, we provide first comprehensive data on HRQL in
real life settings in Germany of a large ILD cohort and
compared a ILD-specific HRQL questionnaire (K-BILD)
with the generic EQ-5D-5L in order to examine its
suitability to measure HRQL of ILD patients in a
German setting.
In summary our results show, that K-BILD is well ac-
cepted among patients (low number of missing values)
and its results in Germany are comparable to those of
other studies [9, 10, 28], thus supporting the use of
K-BILD in Germany. Additionally, further analysis
showed the EQ-5D-5L to have properties similar to the
K-BILD and hence allowing its use in the ILD disease
group, and open up comparability of ILD disease burden
in terms of HRQL to that of other diseases as well as to
HRQL in the general population.
Both instruments lack floor and ceiling effects, indicating
that they should be able to detect changes in the patients
HRQL over time, which is important for further clinical
research. Accordingly, the implementation of these
tools could promote better understanding of the
impairments in ILD in different countries, among
different study populations and the HRQL development
throughout time.
Our study was the first applying the K-BILD in a
German observational study and comparisons to inter-
national evidence need to be interpreted keeping
different healthcare environment and patient preferences
in mind. Three studies from different European contries
reported comparable mean K-BILD scores as our study
[9, 10, 28] Additionally, in line with our findings, the
ILD patients of the Wapenaar study had the greatest
impairment in the ‘breathlessness and activity’ domain,
followed by ‘psychological impact’ and ‘chest symptoms’.
This strongly supports the international transferability
and applicability of K-BILD. Despite the high concord-
ance of K-BILD scores cross-nationally and the lack of
any other ILD-specific questionnaire, the tool is sparsely
used. Our results suggest that a more frequent use
would be beneficial.
Table 5 Results of regression analyses for the comorbidities in the secondary analysis
K-BILD
EQ-5D EBVS VAS Total Breathlessness Chest symptoms Psychological impact
Est. Est. Est. Est. Est. Est.
Comorbidities
Pulmonary hypertension −0.02 2.99 2.43 1.74 5.71 3.33
Arterial hypertension −0.05* −2.96 −2.75 −6.85* −1.04 − 2.08
Coronary heart disease −0.02 −4.70 −2.06 − 2.90 −5.97 − 2.51
Congestive heart failure 0.05 −4.57 2.12 3.22 3.81 1.81
Other CVD 0.02 10.96 4.07 0.98 16.60 5.34
Diabetes mellitus −0.03 −0.96 −1.89 0.35 −3.94 −1.91
Emphysema/COPD −0.06 − 3.02 − 3.18 −6.03 −9.11 −2.38
Lung cancer 0 0 0 0 0 0
Depression −0.08 −5.27 −5.36 −5.69 −17.04** −5.87
GERD 0.04 −6.87 −0.86 −1.72 −4.39 −2.62
Renal failure 0.08 2.83 3.79 8.87 6.28 1.82
OSAS −0.05 −6.11 −1.71 −3.66 −8.22 −1.44
Thromboembolism −0.11 −2.82 −2.27 0.31 −9.70 −4.93
Malignant tumor −0.01 −13.66 −0.68 3.60 −13.06 −1.28
Values depicted are the beta estimates of regression coefficients,all adjusted for age, sex, education, employment,clinic location, smoking status, FVC % pred,
DLCO % pred, disease suptype. Abbreviations Est-estimates, IPF idiopathic pulmonary fibrosis, HP: hypersensitivity pnemonitis 1including: non-specific interstitial
pneumonia, desquamative interstitial pneumonia, cryptogenetic organizing pneumonia, lymphocytic interstitial pneumonia,respiratory bronchiolitis associated
interstitial lung disease, pleuropulmonary fibroelastosis, and acute interstitial pneumonia. *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001
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K-BILD showed strong correlation with the EQ-5D
EBVS, suggesting that it measures similar aspects. At the
same time, K-BILD showed stronger correlations with lung
function parameters than EQ-5D-5L. This emphasizes the
assumption that K-BILD may be more suitable to detect
the impairments originating from ILD. Since EQ-5D-5L
might not be sensitive enough in case of disease-specific
conditions [29], it is especially important to find a valid
instrument measuring disease-specific burden to foster a
more targeted patient-centered ILD management.
The trend of lower correlations between the HRQL
domains highlights once more the difference between
generic and disease-specific questionnaires, but the
high correlation of the K-BILD and EQ-5D EBVS allows
us to still assume a good overall picture about the
HRQL. Our results show in almost all cases slightly
lower but still comparable correlation coefficients
(EQ-5D, VAS vs K-BILD and its domains) than from
the language validation from Wapenaar et al. [10].
Furthermore, reliability measured with Chronbach’s
alpha showed comparable results (good or moderate) as
in Patel et al. [9] and in Wapenaar et al. [10], proving
the consistency of K-BILD.
As expected EQ-5D EBVS reacted more sensitive to
sociodemographic factors (age, sex) and socioeconomic
status (employment) than K-BILD, since generic instru-
ments are known to implicitly cover generic health
aspects more comprehensively than disease-specific
ones. The unexpected results of the association of higher
age with higher HRQL could occur because older people
have lower expectations regarding HRQL or maybe
because of further undetected covariables, for which are
not accounted in this setting. The disease-specific
K-BILD showed in the domains ‘breathlessness and
activity’ and ‘chest symptoms’ a high sensitivity for the
lung function value FVC % pred. These findings are in
contradiction with Coelho et al., who did not find any
association by applying Medical Outcomes Study Short
Form 36 -item questionnaire and SGRQ [8]. This could
be due to the lower number of patients or due to use of
a different HRQL assessment tool in their study. Worth
mentioning, HRQL assessment tools are meant to
quantify important aspects of the patients’ subjective
well-being than objective clinical outcomes, therefore
low correlations between lung function values and
HRQL seem to be tolerable.
Results from King et al. as well as from Kreuter et al.
suggest that increasing comorbidity burden is associated
with increased morbidity and mortality [30, 31]. Apart
from these hard outcomes, the number of comorbid
conditions has apparently also a detrimental effect on
self-rated HRQL of ILD patients. Therefore, improved
comorbidity management in ILD patients might not only
reduce the mortality risk itself but also contribute to
improve HRQL. In this regard, the generic EQ-5D EBVS
and VAS react stronger to comorbidity than K-BILD.
The reason could be the high severity of the ILD and
thus overpowering other comorbidities in the psycho-
logical aspects. Even though our study population
differed regarding their HRQL from the excluded
patients (showed significantly lower values), the sensitivity
analysis confirmed our primary results.
The secondary analysis revealed that, despite the
significant association between comorbidity burden and
HRQL, only a few distinct comorbidities seem decisive
for HRQL. Depression was negatively associated with
HRQL in the ‘chest symptoms’ domain. This could
reflect the high burden of the underlying ILD or could
be due to the general association between chest pain and
depression independent of ILD [32]. The lack of associ-
ation between HRQL and other comorbidities could be
due to the low number of patients for the distinct
comorbidities. Furthermore, these results suggest the
additivity of the effects of the comorbidities on HRQL.
There is no clinical evidence for the measured
higher impairment of sarcoidosis patients in compari-
son with other subtypes yet; further research is
needed in this regard. A possible explanation could
be that compared to diseases restricted to the lungs,
e.g. IPF or HP, sarcoidosis is a systemic disease with
systemic consequences.
Our findings have to be interpreted under some
caveats. As with any observational cross-sectional study,
our results show associations but causality cannot be
tested. Controlling for confounders was the best strategy
to address this issue but some important confounder
might have been overlooked. Furthermore, this study
was voluntary, therefore selection bias cannot be ruled
out. Given the high accordance of our findings to inter-
national evidence on K-BILD, we consider selection bias
to be of minor importance. Additionally, the results may
not be generalizable to populations outside Germany.
The crucial strength of our study is that we applied
K-BILD for the first time in a German setting in a com-
paratively large patient cohort consisting of individuals
with various subtypes located on quite distant geo-
graphic location. This enables general conclusions on
the suitability of K-BILD as the disease-specific HRQL
measurement of choice.
Conclusion
In conclusion, K-BILD and EQ-5D revealed similar
HRQL trends and were sensitive to the same
disease-related factors. K-BILD reacted more sensitively
to ILD-specific aspects of HRQL rendering it a valuable
complementary measure to the generic EQ-5D-5L.
Therefore, we propose that K-BILD should be imple-
mented as standard tool in clinical practice.
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